Mass Production of Monoclonal Antibodies

  • H. Baumgarten
  • R. Franze
  • J. H. Peters
  • A. Borgya
  • D. Baron
  • E. Debus
  • M. Kubbies
Part of the Springer Laboratory book series (SLM)


The production of large amounts of monoclonal antibodies (MAB) (Fig. 25) has increased in importance proportionately as these are used increasingly in human and veterinary medical diagnostics, in agriculture and also, finally, in therapeutic procedures in humans. No longer are only a few micro- or milligrams required for analytical purposes, but rather gram or even sometimes kilogram amounts are required. To produce such amounts as ascites fluid can scarcely be answered for on ethical grounds, and so nowadays, fortunately, large amounts of MAB are produced essentially entirely in vitro, i.e., in bioreactors (Kuhlmann et al. 1989). A variety of additional practical reasons also speak for in vitro production:
  1. 1.

    The use of cell culture supernates is always necessary if antibodies produced in the body of a mouse (ascites) would be a disturbing factor. A pure monoclonal antibody can be obtained practically only from serum-free culture.

  2. 2.

    An important advantage of serum-free cell culture is that the antibodies can be purified relatively simply.

  3. 3.

    The more an in vitro reactor system resembles the extremely efficient “bioreactor mouse” in physiological and physiochemical respects, the higher its efficiency, which is synonymous with high quantity, high quality and economical MAB production. Meanwhile, the bioreactor systems available show significant advantages over the bioreactor mouse in respect of reproducability, scale-up, surveillance, and control.



Hollow Fiber Draught Tube Spinner Flask Immunol Method Severe Combine Immunodeficiency Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Freshney RI (ed) (1985) Animal cell culture. A practical approach. IRL Press, OxfordGoogle Scholar
  2. Hay RJ (1988) The seed stock concept and quality control for cell lines. Anal Biochem 171:225–237PubMedCrossRefGoogle Scholar
  3. Kuhlmann I, Kurth W, Ruhdehl I (1989) Monoclonal antibodies: in vivo and in vitro production on a laboratory scale, with consideration of the legal aspects of animal protection. Alternatives Lab Anim 17:73–82Google Scholar


  1. Brodeur BR, Tsang PS (1986) High yield monoclonal antibody production in ascites. J Immunol Methods 86:239–241PubMedCrossRefGoogle Scholar
  2. Brodeur BR, Tsang P, Larose Y (1984) Parameters affecting ascites tumor formation in mice and monoclonal antibody production. J Immunol Methods 71:265–272PubMedCrossRefGoogle Scholar
  3. Coll JM (1987) Injection of physiological saline facilitates recovery of ascitic fluids for monoclonal antibody production. J Immunol Methods 104:219–222PubMedCrossRefGoogle Scholar
  4. Dobbelaere DAE, Spooner PR (1985) Production in ascites fluid of biosynthetically labelled monoclonal antibody to Theileria parva sporozoites. J Immunol Methods 82:209–214PubMedCrossRefGoogle Scholar
  5. Garrett LR, Pascual DW, Clem LW, Cuchens MA (1987) Conformational changes in the DNA of hybridoma cells from pristan treated mice. Chem-Biol Interact 61:249–263PubMedCrossRefGoogle Scholar
  6. Gilette RW (1987) Alternatives to pristan priming for ascitic fluid and monoclonal antibody production. J Immunol Methods 99:21–23CrossRefGoogle Scholar
  7. Hoogenrad N, Helman T, Hoogenrad J (1983) The effect of pre-injection of mice with pristan on ascites tumour formation and monoclonal antibody formation. J Immunol Methods 61:317–320CrossRefGoogle Scholar
  8. Keep PA, Rawlins GA, Bagshawe JAD, Rogers GT, Pentycross CR (1984) Serial ascitic fluid tapping and monoclonal antibody yield in passaged mice. Exp Clin Cancer Res 3:235–238Google Scholar
  9. Matthew WD, Sandrock AW (1987) Cyclophosphamide treatment used to manipulate the immune response for the production of monoclonal antibodies. J Immunol Methods 100:73–82PubMedCrossRefGoogle Scholar
  10. Mueller UW, Hawes CS, Jones WR (1986) Monoclonal antibody production by hybridoma growth in Freund’s adjuvant primed mice. J Immunol Methods 87:193–196PubMedCrossRefGoogle Scholar
  11. Potter M, Boyce CR (1962) Induction of plasma cell neoplasms in strain BALB/c mice with mineral oil adjuvants. Nature 193:1086–1087PubMedCrossRefGoogle Scholar
  12. Tung AS (1983) Production of large amounts of antibodies, nonspecific immunoglobulins, and other serum proteins in ascitic fluid of individual mice and guinea pigs. Methods Enzymol 93:12–23PubMedCrossRefGoogle Scholar
  13. Ware CF, Donato NJ, Dorshkind K (1985) Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID). J Immunol Methods 85:353–361PubMedCrossRefGoogle Scholar
  14. Weismann D, Parker DJ, Rothstein TL, Marshak-Rothstein A (1985) Methods for the production of xenogeneic monoclonal antibodies in murine ascites. J Immunol 135:1001–1003Google Scholar
  15. Witte PL, Ber R (1983) Improved efficiency of hybridoma ascites production by intrasplenic inoculation in mice. JNCI 70:575–577PubMedGoogle Scholar


  1. Abrams PG, Ochs JJ, Giardina SL, Morgan AC, Wilburn SB, Wilt AR, Oldham RK, Foon KA (1984) Production of large quantities of human immunoglobulin in the ascites of athymic mice: implications for the development of anti-human idiotype monoclonal antibodies. J Immunol 132:1611–1613PubMedGoogle Scholar
  2. Kozbor D, Abramow-Newerly W, Triputti P, Cole SPC, Weibel J, Roder JC, Croce CM (1985) Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas. J Immunol Methods 81:31–42PubMedCrossRefGoogle Scholar
  3. Truitt KE, Larrick JW, Raubitschek AA, Buck DW, Jacobson SW (1984) Production of human monoclonal antibody in mouse ascites. Hybridoma 3:195–199PubMedCrossRefGoogle Scholar


  1. Adamson SR, Fitzpatrick SL, Behie LA (1983) In vitro production of high titre monoclonal antibody by hybridoma cells in dialysis cultures. Biotechnol Lett 5:573–578CrossRefGoogle Scholar
  2. Altshuler GL, Dziewulski DM, Sowek JA, Beifort G (1986) Continuous hybridoma growth and monoclonal antibody production in hollow fiber reactors-separators. Biotechnol Bioeng 28:646–658PubMedCrossRefGoogle Scholar
  3. Arathoon WR, Birch JR (1986) Large-scale cell culture in biotechnology. Science 232:1390–1395PubMedCrossRefGoogle Scholar
  4. Bañó MC, Cohen S, Visscher KB, Allcock HR, Langer R (1991) A novel synthetic method for hybridoma cell encapsulation. Biothechnology 9:468–471CrossRefGoogle Scholar
  5. de Bruyne NA, Morgan BJ (1981) Stirrers for suspension cell cultures. Am Lab JuneGoogle Scholar
  6. Comer MJ, Kearns MJ, Wahl J, Munster M, Lorenz T, Szperalski B, Koch S, Behrendt U, Brunner H (1990) Industrial production of monoclonal antibodies and therapeutic proteins by dialysis fermentation. Cytotechnology 3:295–299PubMedCrossRefGoogle Scholar
  7. Evans TL, Miller RA (1988) Large-scale production of murine monoclonal antibodies using hollow fiber bioreactors. Bio Techniques 6:762–767Google Scholar
  8. Fazekas de St. Groth S (1983) Automated production of monoclonal antibodies in a cytostat. J Immunol Methods 57:121–136PubMedCrossRefGoogle Scholar
  9. Hopkinson J (1985) Hollow fiber cell culture systems for economical cell-product manufacturing. Biotechnol Bioeng 3:225ffGoogle Scholar
  10. Killinger A (1988) Zellzucht im industriellen Maßstab. Biotech-Forum 4:260–262Google Scholar
  11. Klerx JPAM, Jansen Verplanke C, Blonk CG, Twaalfhoven LC (1988) In vitro production of monoclonal antibodies under serum-free conditions using a compact and inexpensive hollow fibre cell culture unit. J Immunol Methods 111:179–188PubMedCrossRefGoogle Scholar
  12. Ku K, Kuo MJ, Delente J, Wild BS, Feder J (1981) Development of a hollow-fiber system for large-scale culture of mammalian cells. Biotechnol Bioeng 23:79–87CrossRefGoogle Scholar
  13. Lazar A, Silberstein L, Mizrahi A, Reuveny S (1988) An immobilized hybridoma culture perfusion system for production of monoclonal antibodies. Cytotechnol 1:331–337CrossRefGoogle Scholar
  14. Lehmann J, Piehl GW, Schulz R (1985) Blasenfreie Zellkulturbegasung mit bewegten, porösen Membranen. Biotech-Forum 2Google Scholar
  15. Lim F (1984) Microencapsulation of living cells and tissues — theory and practice in biomedical applications of microencapsulation. CRC Press, Boca Raton pp 137–154Google Scholar
  16. Martial A, Dardenne M, Engasser J-M, Marc A (1991) Influence of inoculum age on hybridoma culture kinetics. Cytotechnology 5:165–171PubMedCrossRefGoogle Scholar
  17. Mizrahi A (1986) Production of biologicals from animal cells — an overview. Proc Biochem Aug: 108–112Google Scholar
  18. Nilsson K, Birnbaum L, Lygare S, Linse L, Schröder U, Jeppson U, Larsson P-O (1983) A general method for the immobilization of cells with preserved viability. Eur J Appl Microbiol Biotechnol 17:319–326CrossRefGoogle Scholar
  19. Randerson DH (1985) Large-scale cultivation of hybridoma cells. J Biotechnol 2:2451–255CrossRefGoogle Scholar
  20. Ratafia M (1986) Current issues in the scale-up of biotechnology processes. Pharm Technol June:42–52Google Scholar
  21. Reuveny S, Velez D, Macmilan JD, Miller L (1986) Factors affecting cell growth and monoclonal antibody production in stirred reactors. J Immunol Methods 86:53–59PubMedCrossRefGoogle Scholar
  22. Sjögren-Jansson E, Jeansson S (1985) Large-scale production of monoclonal antibodies in dialysis tubing. J Immunol Methods 84:359–364PubMedCrossRefGoogle Scholar
  23. Tanaka H, Masatoni M, Vellky IA (1984) Diffusion characteristics of substrates in Ca-alginate gel beads. Biotechnol Bioeng 26:53–58PubMedCrossRefGoogle Scholar
  24. Tharakan JP, Chau PC (1986) A radial flow hollow fiber bioreactor for the large-scale culture of mammalian cells. Biotechnol Bioeng 28:329–342PubMedCrossRefGoogle Scholar
  25. Tutunjian RS, Sewing R (1984) Hollow-Fiber-Ultrafiltration in der Biotechnologie. Biotech-Forum 3Google Scholar
  26. van Brunt J (1987) A closer look at fermentors. Bio Technology 5:1133–1142Google Scholar
  27. Wilke H-P, Weber C, Fries T (1988) Rührtechnik: Verfahrenstechnische und apparative Grundlagen. Hüthig, HeidelbergGoogle Scholar

Further Reading

  1. Deckwer W-D (1987) Bioreaktoren: Ein Leitfaden für Anwender. Gesellschaft für Biotechnologische Forschung mbH, BraunschweigGoogle Scholar
  2. Freshney RI (1986) Animal cell culture: a practical approach. IRL Press, OxfordGoogle Scholar
  3. Lydersen BK (1987) Large scale cell culture technology. Hanser Publishers, MunichGoogle Scholar
  4. Seaver SS (ed) (1987) Commercial production of monoclonal antibodies. Marcel Dekker, New YorkGoogle Scholar
  5. Spier RE, Griffiths JB (1987) Modern approaches to animal cell technology. Butterworth, Sevenoaks, EnglandGoogle Scholar


  1. Barnes D, Sato GH (1980a) Methods for growth of cultured cells in serum-free medium. Anal Biochem 102:255–70PubMedCrossRefGoogle Scholar
  2. Barnes D, Sato G (1980b) Serum-free culture: a unifying approach. Cell 22:649–655PubMedCrossRefGoogle Scholar
  3. Cleveland WL, Wood I, Erlanger BF (1983) Routine large-scale production of monoclonal antibodies in a protein-free culture medium. J Immunol Methods 56:221–234PubMedCrossRefGoogle Scholar
  4. Chang TH, Steplewski Z, Koprowski H (1980) Production of monoclonal antibodies in serum free medium. J Immunol Methods 39:369–375PubMedCrossRefGoogle Scholar
  5. Glassy MC, Peters RE, Mikhalev A (1987) Growth of human-human hybridomas in serumfree media enhances antibody production. In Vitro Cell Dev Biol 23:745–749PubMedCrossRefGoogle Scholar
  6. Glassy MC, Tharakan JP, Chau PC (1988) Serum-free media in hybridoma culture and monoclonal antibody production. Biotechnol 32:1015–1028Google Scholar
  7. Griffiths B (1986) Can cell culture medium costs be reduced? Strategies and possibilities. TIB-TECH October:268–272Google Scholar
  8. Jayme DW, Epstein DA, Conrad DR (1988) Fetal bovine serum alternatives. Nature 334:547–548PubMedCrossRefGoogle Scholar
  9. Kawamoto T, Sato JD, Le A, McClure DB, Sato GH (1983) Development of a serum-free medium for growth of NS-1 mouse myeloma cells and its application to the isolation of NS-1 hybridomas. Anal Biochem 130:445–453PubMedCrossRefGoogle Scholar
  10. Kawamoto T, Sato JD, McClure DB, Sato GH (1986) Serum-free medium for the growth of NS-1 mouse myeloma cells and the isolation of NS-1 hybridomas. Methods Enzymol 121:266–292PubMedCrossRefGoogle Scholar
  11. Kovar J (1986) Hybridoma cultivation in defined serum-free media-growth supporting substances III. ethanolamine, vitamins and other low molecular weight nutrients. Folio Biol (Prague) 32:369–376Google Scholar
  12. Kovar J, Franek F (1984) Serum-free medium for hybridoma and parental myeloma cell cultivation: a novel compositon of growth-supporting substances. Immunol Lett 7:339–345PubMedCrossRefGoogle Scholar
  13. Kovar J, Franek F (1987) Iron compounds at high concentrations enable hybridoma growth in a protein free-medium. Biotechnol Lett 9:259–264CrossRefGoogle Scholar
  14. Mizrahi A, Lazar A (1988) Media for cultivation of animal cells: an overview. Cytotechnology 1:199–214Google Scholar
  15. Murakami H, Masui H, Sato GH, Sueoka N, Chow TP, Kano-Sueoka T (1982) Growth of hybridoma cells in serum-free medium: ethanolamine is an essential component. Proc Natil Acad Sci USA 79:1158–1162CrossRefGoogle Scholar
  16. Samoilovich S, Dugan CB, Macario AJL (1987) Hybridoma technology: new developments of practical interest. J Immunol Methods 101:153–170PubMedCrossRefGoogle Scholar
  17. Schacter E (1987) Serum-free medium for growth factor-dependent and -independent plasmo-cytomas and hybridomas. J Immunol Methods 99:259–270CrossRefGoogle Scholar
  18. Tharakan JP, Chau PC (1986) IgG production kinetics in serum free medium. Biotechnol Lett 8:529–534CrossRefGoogle Scholar
  19. Waymouth C (1984) Preparation and use of serum-free culture media. In: Methods for preparation of media supplements, and substrata for serum-free animal cell culture. Liss, New York, pp 23–68Google Scholar


  1. Hamilton RG, Reimer CB, Rodkey LS (1987) Quality control of murine monoclonal antibodies using isoelectric focusing affinity immunoblot analysis. Hybridoma 6:205–217PubMedCrossRefGoogle Scholar
  2. Rickard EC, Stittampalam GS, Clodfelter DK (1988) Protein assays for monoclonal antibodies. Bio-Techniques 6:982–992Google Scholar


  1. Thornthwaite JT, Everett D, Sugarbaker V, Temple WJ (1980) Preparation of tissues for DNA flow cytometric analysis. Cytometry 1:229–237PubMedCrossRefGoogle Scholar
  2. Vindelov LL, Christensen IJ, Nissen NI (1983) Standardization of high-resolution flow cytometric DNA-analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry 3:328–331PubMedCrossRefGoogle Scholar
  3. Tietz F, Friedl R, Hoehn H, Kubbies M (1987) Determination of base pair ratio and DNA content in mammalian species using flow cytometry. In: Burger G, Ploem JS, Goerttler K (eds) Clinical histometry and cytometry. Academic Press, New York, pp 189–191Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. Baumgarten
  • R. Franze
  • J. H. Peters
  • A. Borgya
  • D. Baron
  • E. Debus
  • M. Kubbies

There are no affiliations available

Personalised recommendations